XML 60 R24.htm IDEA: XBRL DOCUMENT
v3.19.3

Intangible Assets and Goodwill (Tables) | 9 Months Ended
--- | ---
Sep. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets and Goodwill |
(Dollars in Millions) |  | September 29, 2019 |  | December 30, 2018
Intangible assets with definite lives: |  |  |  |
Patents and trademarks — gross |  | $ | 36,114 |  |  | 35,194 |
Less accumulated amortization |  | 12,158 |  |  | 9,784 |
Patents and trademarks — net |  | 23,956 |  |  | 25,410 |
Customer relationships and other intangibles — gross |  | 21,845 |  |  | 21,334 |
Less accumulated amortization |  | 9,120 |  |  | 8,323 |
Customer relationships and other intangibles — net |  | 12,725 |  |  | 13,011 |
Intangible assets with indefinite lives: |  |  |  |
Trademarks |  | 6,875 |  |  | 6,937 |
Purchased in-process research and development (1) |  | 4,290 |  |  | 2,253 |
Total intangible assets with indefinite lives |  | 11,165 |  |  | 9,190 |
Total intangible assets — net |  | $ | 47,846 |  |  | 47,611 |
(1)In the fiscal first quarter of 2019, the Company recorded an IPR&D impairment charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter of 2018 related to the development program of AL-8176. In the fiscal second quarter of 2019, the Company completed the acquisition of Auris Health, Inc. and recorded an in-process research and development intangible asset of $2.9 billion.
Goodwill | Goodwill as of September 29, 2019 was allocated by segment of business as follows:
(Dollars in Millions) |  | Consumer |  | Pharm |  | Med Devices |  | Total
Goodwill at December 30, 2018 |  | $ | 8,670 |  |  | 9,063 |  |  | 12,720 |  |  | 30,453 |
Goodwill, related to acquisitions |  | 1,191 |  |  | — |  |  | 2,018 |  |  | 3,209 |
Currency translation/Other |  | (266 | ) |  | (86 | ) |  | (19 | ) |  | (371 | )
Goodwill at September 29, 2019 |  | $ | 9,595 |  |  | 8,977 |  |  | 14,719 |  |  | 33,291 |

X
- Definition Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block] + References No definition available. + Details
Name: | jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock
Namespace Prefix: | jnj_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267 + Details
Name: | us-gaap_ScheduleOfGoodwillTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration